1. Medtech Insight

An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024

Companies Can Often Use Wales’ Relatively Small Market Size To Their Advantage

 
• By Ashley Yeo

Creo Medical and Clinithink are among healthtech innovators that have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

Shutterstock

[Editor's note:A version of this article originally appeared in In Vivo.]

Creo Medical, a UK provider of minimally invasive surgical endoscopy for pre-cancer and cancer patients, is an innovation and funding success

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.